A bald man with a mustache wearing a dark suit, light blue shirt, and patterned tie, smiling in front of a plain gray background.

Leslie Citrome, MD, MPH

Adjunct Professor of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

JCP
Transdermal HP-3070 for Hostility in Schizophrenia
Original Research

June 6, 2022

Schizophrenia is sometimes accompanied by aggressive, hostile behavior, particularly during the acute phase. This post hoc analysis of a phase 3 study examines the efficacy of transdermal asenapine (HP-3070)...
, , , et al
JCP
Educational Activity

October 12, 2021

Can you recognize risk factors for tardive dyskinesia? Are you familiar with diagnostic criteria? Do you regularly assess patients for the condition? Are you knowledgeable about using new medications...
,
JCP
Academic Highlights

August 31, 2021

Experts offer a review of the fundamentals of diagnosing and treating tardive dyskinesia.
,
JCP
Original Research

June 1, 2021

Many pharmacologic treatment options are available for insomnia. In this study, the clinical utility of the new hypnotic lemborexant is given clinical perspective via the evidence-based medicine tools of...
, , , et al
JCP
Writing, Reviewing, and Publishing Scientific Articles, Part 2: Demystifying the Manuscript Submission Process
Insights

May 24, 2021

Editor of the ASCP Corner shares his thoughts, especially for early career psychiatrists, on writing and submitting your manuscript in such a way as to remove fear from the...
JCP
Original Research

December 15, 2020

Transdermal asenapine administration may address unmet needs in patients with schizophrenia, including improved adherence. This phase 3 study assessed efficacy and safety of HP-3070, an asenapine transdermal system (patch),...
, , , et al
JCP
Consensus Statement

May 19, 2020

The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this...
, , , et al
JCP
Original Research

March 10, 2020

Alcohol use disorder is comorbid in 33% of US patients with schizophrenia. Testing the tolerability of olanzapine and samidorphan until the first event of exacerbation of disease symptoms is...
, , , et al
JCP
Consensus Statement

January 28, 2020

Tardive dyskinesia remains a serious complication associated with dopamine receptor blocking agents. In this article, read guidance from experts on best practices for tardive dyskinesia screening, diagnosis, and treatment.
, , , et al
JCP
ASCP Corner

December 4, 2019

Are electronic prescribing alerts useful or simply annoying? A survey gathered the opinions of ASCP members on several aspects of these alerts, including how often they are inaccurate and...
,
JCP
Educational Activity

July 30, 2019

New mechanisms of action present new opportunities to improve outcomes for patients with depression. Listen to a panel of experts discuss best practices and novel antidepressants at the 2019...
, , , et al
JCP
Review Article

July 16, 2019

Transdermal delivery is an alternative to oral routes of drug administration. This delivery route has several innate advantages that may benefit patients with CNS disorders—read this Expert Commentary to...
, ,

Watch the New PsychCase360

Explore two real-world schizophrenia cases
Promotional banner for a video titled “Choosing the Right LAI for Patients With Schizophrenia” featuring headshots of Roueen Rafeyan, MD, and Melissa Vitale, PMHNP, with a “Watch Now” button.

Subscribe to read
more articles

Subscribe